3 Red-Hot Stocks That Are Still Dirt Cheap

3 Red-Hot Stocks That Are Still Dirt Cheap
·3 min read

BioNTech and Pfizer look for the vaccine to rake in sales of around $26 billion this year. BioNTech's shares are trading at a seeming bargain because investors aren't sure how much recurring revenue the company will be able to count on after 2022. If booster doses are needed going forward, BioNTech's future sales could be massive for a long time to come.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting